RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Tianjin Pharmaceutical Da Ren Tang Group Corp Stock

Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT 2024

Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT

1.08 B CNY

Ticker

600329.SS

ISIN

CNE000001808

In 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp's EBIT was 1.08 B CNY, a 32.55% increase from the 814.79 M CNY EBIT recorded in the previous year.

The Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT history

YEAREBIT (undefined CNY)
2026e1.65
2025e1.34
2024e1.08
20230.81
20220.68
20210.59
20200.59
20190.54
20180.47
20170.35
20160.3
20150.39
20140.37
20130.34
20120.27
20110.27
20100.24
20090.17
20080.09
2007-0.19
2006-0.41
20050.05
20040.07

Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Tianjin Pharmaceutical Da Ren Tang Group Corp, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Tianjin Pharmaceutical Da Ren Tang Group Corp from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Tianjin Pharmaceutical Da Ren Tang Group Corp’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Tianjin Pharmaceutical Da Ren Tang Group Corp. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Tianjin Pharmaceutical Da Ren Tang Group Corp’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Tianjin Pharmaceutical Da Ren Tang Group Corp’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Tianjin Pharmaceutical Da Ren Tang Group Corp’s growth potential.

Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue, EBIT and net profit per share

DateTianjin Pharmaceutical Da Ren Tang Group Corp RevenueTianjin Pharmaceutical Da Ren Tang Group Corp EBITTianjin Pharmaceutical Da Ren Tang Group Corp Net Income
2026e10.67 B undefined1.65 B undefined1.68 B undefined
2025e9.78 B undefined1.34 B undefined1.42 B undefined
2024e8.97 B undefined1.08 B undefined1.18 B undefined
20238.22 B undefined814.79 M undefined986.71 M undefined
20228.25 B undefined681.08 M undefined861.79 M undefined
20216.91 B undefined592.64 M undefined769.14 M undefined
20206.6 B undefined587.5 M undefined661.7 M undefined
20196.99 B undefined536.8 M undefined625.6 M undefined
20186.36 B undefined468 M undefined561.7 M undefined
20175.69 B undefined348.3 M undefined476.1 M undefined
20166.24 B undefined295.8 M undefined423.6 M undefined
20157.08 B undefined393.2 M undefined451.4 M undefined
20147.09 B undefined372.5 M undefined357.8 M undefined
20136.01 B undefined344.1 M undefined351.8 M undefined
20125.13 B undefined268 M undefined441.3 M undefined
20114.39 B undefined271.9 M undefined247.6 M undefined
20103.47 B undefined236.8 M undefined293.3 M undefined
20092.88 B undefined168.4 M undefined257.8 M undefined
20082.37 B undefined92.5 M undefined176.1 M undefined
20072.26 B undefined-185.7 M undefined-70 M undefined
20062.16 B undefined-408.2 M undefined-386.6 M undefined
20052.52 B undefined51.3 M undefined80.8 M undefined
20042.12 B undefined73.1 M undefined64 M undefined

Tianjin Pharmaceutical Da Ren Tang Group Corp stock margins

The Tianjin Pharmaceutical Da Ren Tang Group Corp margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Tianjin Pharmaceutical Da Ren Tang Group Corp. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Tianjin Pharmaceutical Da Ren Tang Group Corp.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Tianjin Pharmaceutical Da Ren Tang Group Corp's sales revenue. A higher gross margin percentage indicates that the Tianjin Pharmaceutical Da Ren Tang Group Corp retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Tianjin Pharmaceutical Da Ren Tang Group Corp's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Tianjin Pharmaceutical Da Ren Tang Group Corp's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Tianjin Pharmaceutical Da Ren Tang Group Corp's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Tianjin Pharmaceutical Da Ren Tang Group Corp. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Tianjin Pharmaceutical Da Ren Tang Group Corp's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Tianjin Pharmaceutical Da Ren Tang Group Corp Margin History

Tianjin Pharmaceutical Da Ren Tang Group Corp Gross marginTianjin Pharmaceutical Da Ren Tang Group Corp Profit marginTianjin Pharmaceutical Da Ren Tang Group Corp EBIT marginTianjin Pharmaceutical Da Ren Tang Group Corp Profit margin
2026e43.66 %15.5 %15.78 %
2025e43.66 %13.66 %14.54 %
2024e43.66 %12.04 %13.21 %
202343.66 %9.91 %12 %
202239.49 %8.26 %10.45 %
202139.76 %8.58 %11.13 %
202039.07 %8.9 %10.02 %
201941.76 %7.68 %8.94 %
201841.2 %7.36 %8.83 %
201738.68 %6.12 %8.37 %
201632.27 %4.74 %6.79 %
201529.48 %5.55 %6.38 %
201430.27 %5.26 %5.05 %
201331.86 %5.73 %5.85 %
201234.12 %5.22 %8.6 %
201134.85 %6.19 %5.64 %
201037.77 %6.82 %8.44 %
200937.54 %5.85 %8.95 %
200836.93 %3.91 %7.45 %
200734.28 %-8.22 %-3.1 %
200635.01 %-18.86 %-17.86 %
200542.58 %2.04 %3.21 %
200445.13 %3.45 %3.02 %

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktienanalyse

What does Tianjin Pharmaceutical Da Ren Tang Group Corp do?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is one of the leading pharmaceutical companies in China. It was founded in 1994 and is headquartered in the city of Tianjin in the northern part of the country. Zhongxin is a publicly traded company and employs over 6,000 employees. The business model of Zhongxin is diversified and includes manufacturing, research and development, sales, and marketing of pharmaceuticals and medical devices. The company strives to provide its customers with high-quality products and services and operates in various specialized areas. One of Zhongxin's main divisions is the manufacturing of pharmaceutical products. The company specializes in the production of cardiology, gastroenterology, oncology, and traditional Chinese medicines. Zhongxin operates multiple production facilities in China and has a productive R&D department focused on drug development. Another important part of Zhongxin's business is the distribution of its products. The company operates several distribution centers in China and is also increasing its presence in international markets. Distribution is done either directly to end customers or through intermediaries. In addition to the sale of medications, Zhongxin is also involved in medical wholesale activities, including retail and delivery of medical equipment and instruments. The company is capable of providing all types of medical devices and instruments from imaging and diagnostics to surgical instruments and implants. Zhongxin also has a specialized chemicals and raw materials division focused on the production of pharmaceutical active ingredients and intermediates. This gives the company additional control over the quality of its products as it is able to produce raw materials itself. The company is always seeking new innovations and heavily investing in research and development. In recent times, Zhongxin has invested in the development of biotech and nucleic acid therapies and intends to develop further innovative treatment methods. Zhongxin has also developed a strong presence in international markets in recent years. It has subsidiaries in several countries including the USA, Australia, Japan, and Europe. The company engages in joint ventures and strategic partnerships to enhance its raw material procurement and expand its reach internationally. Overall, Tianjin Zhongxin Pharmaceutical Group Corp Ltd is a significant player in the pharmaceutical industry in China and on the international stage. The company has established a reputation as a reliable producer of high-quality medical products and services and continues to strive for success through innovation and expansion. Tianjin Pharmaceutical Da Ren Tang Group Corp ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Tianjin Pharmaceutical Da Ren Tang Group Corp's EBIT

Tianjin Pharmaceutical Da Ren Tang Group Corp's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Tianjin Pharmaceutical Da Ren Tang Group Corp's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Tianjin Pharmaceutical Da Ren Tang Group Corp's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Tianjin Pharmaceutical Da Ren Tang Group Corp’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Tianjin Pharmaceutical Da Ren Tang Group Corp stock

How much did Tianjin Pharmaceutical Da Ren Tang Group Corp achieve in EBIT for the current year?

In the current year, Tianjin Pharmaceutical Da Ren Tang Group Corp has achieved an EBIT of 1.08 B CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Tianjin Pharmaceutical Da Ren Tang Group Corp.

How has the EBIT of Tianjin Pharmaceutical Da Ren Tang Group Corp developed in recent years?

The EBIT of Tianjin Pharmaceutical Da Ren Tang Group Corp has increased by 32.549% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Tianjin Pharmaceutical Da Ren Tang Group Corp?

The EBIT of Tianjin Pharmaceutical Da Ren Tang Group Corp is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Tianjin Pharmaceutical Da Ren Tang Group Corp pay?

Over the past 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corp paid a dividend of 1.12 CNY . This corresponds to a dividend yield of about 4.24 %. For the coming 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corp is expected to pay a dividend of 1.21 CNY.

What is the dividend yield of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The current dividend yield of Tianjin Pharmaceutical Da Ren Tang Group Corp is 4.24 %.

When does Tianjin Pharmaceutical Da Ren Tang Group Corp pay dividends?

Tianjin Pharmaceutical Da Ren Tang Group Corp pays a quarterly dividend. This is distributed in the months of July, July, July, August.

How secure is the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Pharmaceutical Da Ren Tang Group Corp paid dividends every year for the past 16 years.

What is the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp?

For the upcoming 12 months, dividends amounting to 1.21 CNY are expected. This corresponds to a dividend yield of 4.58 %.

In which sector is Tianjin Pharmaceutical Da Ren Tang Group Corp located?

Tianjin Pharmaceutical Da Ren Tang Group Corp is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tianjin Pharmaceutical Da Ren Tang Group Corp kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp from 7/12/2024 amounting to 1.28 CNY, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Tianjin Pharmaceutical Da Ren Tang Group Corp pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp in the year 2023?

In the year 2023, Tianjin Pharmaceutical Da Ren Tang Group Corp distributed 0.5 CNY as dividends.

In which currency does Tianjin Pharmaceutical Da Ren Tang Group Corp pay out the dividend?

The dividends of Tianjin Pharmaceutical Da Ren Tang Group Corp are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Tianjin Pharmaceutical Da Ren Tang Group Corp

Our stock analysis for Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.